Mesothelioma

Four Attorneys in The Lanier Law Firm's New York Office Honored on 2023 List of NY Metro Super Lawyers

Retrieved on: 
Thursday, September 28, 2023
Mesothelioma, Rising Stars Challenge, Madison Avenue, Lung cancer, Ovarian cancer, Asbestos-related diseases, Research, Thomson Reuters, Lawyer, Personal injury, Insurance, Practice of law

NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Four attorneys from The Lanier Law Firm have earned spots on the 2023 New York Metro Super Lawyers list.

Key Points: 
  • NEW YORK, Sept. 28, 2023 /PRNewswire/ -- Four attorneys from The Lanier Law Firm have earned spots on the 2023 New York Metro Super Lawyers list.
  • Evan M. Janush, the Managing Attorney of the firm's New York office, is named to the list for the 11th consecutive year.
  • The firm's Darron Berquist is honored for the first time on the New York Super Lawyers list, following nine consecutive years of recognition as a Rising Star in the profession.
  • This group joins 11 other firm attorneys named last month to the 2023 list of Texas Super Lawyers.

Cancer Victims Applaud Senate Judiciary Committee Probe into Corporate Manipulation of Chapter 11 Bankruptcy

Retrieved on: 
Tuesday, September 19, 2023
Supreme, Senate Judiciary Committee reviews of nominations to the Supreme Court of the United States, Senate, Woman, Human, J&J, Johnson & Johnson, Hearing, Supreme court, Mesothelioma, Republican, Haas, Ovarian cancer, Bankruptcy, Injury, Tobacco

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Johnson & Johnson's discredited "Texas two-step" bankruptcy efforts came under fire today from witnesses and members of the Senate Judiciary Committee chaired by Sen. Dick Durbin.

Key Points: 
  • Sen. Hawley told Haas, "Your company panics and what you do is you then decide, 'Oh my gosh, we can't possibly do this.
  • It forces victims who may be suffering fatal progressive diseases to endure protracted bankruptcy proceedings, robbing them of "precious time."
  • An appellate court and a bankruptcy judge have twice dismissed J&J's bankruptcy maneuvers, finding that they were filed in bad faith.
  • After a long delay caused by the bankruptcy litigation, attorneys for plaintiffs are gearing up to renew trying their cases before juries.

RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability

Retrieved on: 
Wednesday, September 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Malignant pleural effusion, Tissue, Partnership, AACR, University, Spatial analysis, Neoplasm, Mesothelioma, Survival, EMT, Lung cancer, Multimedia, Photograph, Drug resistance, Oxidative stress, Glycolysis, Patient, Nature, Lunch, RS, University of Leicester, Hypoxia, Conference, Leicester, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230912702236/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230912702236/en/
    “Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options.
  • Our findings here might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study.
  • (Photo courtesy of George Naumov)
    Mesotheliomas can transform from a less aggressive epithelioid malignancy to a more aggressive sarcomatoid form.
  • RSO-021 treatment reversed the gene signatures associated with epithelial-to-sarcomatoid transition, including downregulation of hypoxia, glycolysis, and epithelial-to-mesenchymal transition (EMT)-associated genes.

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreversible Inhibitor of Mitochondrial PRX3

Retrieved on: 
Tuesday, September 12, 2023
Biotechnology, Infectious Diseases, Health, Radiology, Oncology, Lung, RS, Mesothelioma, Cancer, Patient, Caregiver, Safety, Pharmaceutical industry

RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of the Phase 1 dose escalation portion of the MITOPE study ( NCT05278975 ).

Key Points: 
  • RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of the Phase 1 dose escalation portion of the MITOPE study ( NCT05278975 ).
  • The United Kingdom-based multicenter study met its primary objective of evaluating the safety and tolerability of RSO-021, a novel irreversible inhibitor of mitochondrial PRX3, in patients with malignant pleural mesothelioma and local disease affecting the lining of the lungs.
  • These patients also had fluid on their lungs due to the cancer, which had failed to respond to at least one prior treatment.
  • "Concluding Phase 1 is a significant accomplishment towards bringing a potential new therapy to patients suffering from mesothelioma and other cancers of the lung,” said Jarrett Duncan, CEO of RS Oncology.

Simon Greenstone Panatier Ranked Among Top Dallas-based Personal Injury Law Firms

Retrieved on: 
Tuesday, September 12, 2023
Workplace, Mesothelioma, PC, Health, DWI, Family, Lawyer, Personal injury, Asbestos, Frank Andrews (Texas lawyer), Public, Practice of law, Insurance

DALLAS, Sept. 12, 2023 /PRNewswire/ -- Widely recognized for its nationwide representation of plaintiffs involved in toxic tort, mass tort and catastrophic personal injury litigation, Simon Greenstone Panatier, PC, has been selected among the top personal injury law firms in Texas Lawyer magazine's reader-voted "Best Of" survey.

Key Points: 
  • DALLAS, Sept. 12, 2023 /PRNewswire/ -- Widely recognized for its nationwide representation of plaintiffs involved in toxic tort, mass tort and catastrophic personal injury litigation, Simon Greenstone Panatier, PC, has been selected among the top personal injury law firms in Texas Lawyer magazine's reader-voted "Best Of" survey .
  • The firm was one of only three Dallas-based personal injury firms to be recognized in the 2023 survey, which honors the top legal product and service providers in Dallas, Houston and Austin/San Antonio.
  • "The work of a plaintiffs' lawyer is rooted in the desire to improve public safety and health while forcing corporate accountability through the civil justice system," said firm co-founder Jeffrey Simon .
  • The lawyers of Simon Greenstone Panatier have built a reputation for successful litigation in a wide range of personal injury and wrongful death cases.

Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters

Retrieved on: 
Wednesday, September 6, 2023
Firefighter, DNA, Barrett's esophagus, Endoscopy, Partnership, International Association, Cancer, Woman, Market access, Attention, Government, San Antonio Fire Department, Lucid, NJ-5, Federal Fire Prevention and Control Act of 1974, Triage, Representative, Patient, Physician, Risk, Manuscript, SAFD, Esophageal cancer, National Association of Government Employees, Mesothelioma, Pleasure, Delaware Volunteer Firemen's Association, Mortality, MedRxiv, National Association, Louisiana House of Representatives, House, Legislation, Medical imaging, Nursing, Pharmaceutical industry

NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has released positive data from a retrospective analysis demonstrating real-world clinical utility of  EsoGuard® Esophageal DNA testing for the detection of esophageal precancer in a large cohort of fire fighters.

Key Points: 
  • The release of these data closely aligns with and strongly supports recently proposed federal legislation seeking to fund guaranteed firefighter access to early detection tests such as EsoGuard.
  • "Such clinical utility data, along with claims history, has been a key gating item for us to engage payors to secure in-network EsoGuard coverage.
  • 391 SAFD fire fighters who were deemed by a physician to be at-risk for esophageal precancer participated in the event.
  • EsoGuard provides an unprecedented precancer sensitivity of over 80 percent, while no other single or multi-cancer early detection test, blood-based or otherwise, provides any sensitivity in detecting esophageal precancer."

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

Retrieved on: 
Monday, August 28, 2023
Cancer, Therapy, Harbor, Lung cancer, Pharmacokinetics, HKEX, MSLN, Mab, Mesothelioma, ADC, Neoplasm, Ecosystem, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Breast cancer, Pharmaceutical industry

HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.

Key Points: 
  • HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers.
  • HBM9033 utilizes a tumor specific cleavable linker with a novel topoisomerase inhibitor for improved stability and activity.
  • The unique design for both mAb and linker-payload together has demonstrated superior potency and safety of HBM9033 in pre-clinical studies.
  • This phase I study is to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9033 in subjects with advanced solid tumors.

Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial

Retrieved on: 
Tuesday, August 15, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Pancreatic cancer, Learning, Yale School of Medicine, University, Polaris, GBM, Neurology, Hepatocellular carcinoma, Neuro-Oncology (journal), MGMT, Coalition, Survival, Arginine, NDA, Yale school, Multimedia, Cell, Lung cancer, Brain, Associate, Glioblastoma, Global Coalition Against Pneumonia, Assistant, Acute myeloid leukemia, Patient, Melanoma, SAN, Cancer, Mesothelioma, FDA, BLA, Pharmaceutical industry, Medical imaging, Medicine

Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).

Key Points: 
  • Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).
  • GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that evaluates multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230815912018/en/
    Polaris’ ADI-PEG 20 is entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 1,500 patients to date.
  • The ADI-PEG 20 arm of GBM AGILE will be enrolling patients with newly-diagnosed unmethylated MGMT, newly-diagnosed methylated MGMT, and recurrent GBM.

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
BAT, Maintenance, CR2, GPS, University, D, Organic Process Research & Development, Venetoclax, Safety, Mesothelioma, IDMC, American Society of Clinical Oncology, Clinical research associate, Clinical trial, Survival, University of North Carolina, Research, Second, Acute myeloid leukemia, MD Anderson Cancer Center, ASCO, AML, Azacitidine, Bristol Myers Squibb, Doctor of Science, SLS, Patient, Annual general meeting, CR, WT1, Merck & Co., Merck, Ovarian cancer, Merck Sharp & Dohme Federal Credit Union, CDK9, Society, MPM, Nivolumab, Bone marrow, Pharmaceutical industry, Birth control, MD

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023.

Key Points: 
  • NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended June 30, 2023.
  • The next routine IDMC meeting is scheduled for the third quarter of 2023.
  • SELLAS expects to receive milestone payments totaling $13.0 million from 3D Medicines by the end of the third quarter of 2023.
  • Financial Results for the Second Quarter 2023:
    R&D Expenses: Research and development expenses for the second quarter of 2023 were $5.9 million, compared to $5.5 million for the same period in 2022.

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Retrieved on: 
Wednesday, August 9, 2023
Neutropenia, MTAP, Prevalence, MTA, Neoplasm, Mirati Therapeutics, Clinical trial, Cancer Discovery (journal), Cancer, Doctor of Philosophy, Lung, MD Anderson Cancer Center, MD, Patient, SAN, University, Anemia, Mesothelioma, Pulmonary toxicity, Therapy, Kinetics, Thrombocytopenia, PRMT5, Pharmaceutical industry, Vaccine, Medical imaging

SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, announced today Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine (MTA)-cooperative inhibitor evaluated in methylthioadenosine phosphorylase (MTAP) deleted cancers. These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker. The publication can be found here.

Key Points: 
  • These results provide preclinical and early clinical proof-of-concept for this differentiated approach and demonstrate that MRTX1719 may represent a promising targeted therapy for the ~10% of cancer patients with this biomarker.
  • In preclinical studies, MRTX1719 was demonstrated to be a potent, selective inhibitor of the PRMT5/MTA complex.
  • Preclinical results showed marked anti-tumor activity of MRTX1719, including regression, across lung, pancreatic, mesothelioma, and other solid tumor models.
  • "It will be important for next-generation sequencing tests to expand their panel of targets to include for markers of PRMT5 inhibition."